Company: RPTX
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030405
Chunk: 80

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 80
---
 1,921

    1,951

    Non-cash lease expense

    2,359

    2,194

    Foreign exchange loss

    8

    78

    Net accretion of marketable securities

    (5,157
    )

    (7,465
    )

    Changes in operating assets and liabilities:

    Prepaid expenses

    (1,263
    )

    969

    Other current receivables

    2,716

    (216
    )

    Other non-current assets

    217

    101

    Accounts payable

    1,229

    1,934

    Accrued expenses and other current liabilities

    (4,222
    )

    2,412

    Operating lease liabilities, current portion

    (986
    )

    151

    Income taxes

    1,529

    (14,329
    )

    Operating lease liabilities, net of current portion

    (1,325
    )

    (2,373
    )

    Deferred revenue

    (11,952
    )

    (43,832
    )

    Net cash used in operating activities

    (76,445
    )

    (127,158
    )

    Cash Flows From Investing Activities:

    Purchase of property and equipment

    —

    (1,938
    )

    Proceeds from maturities of marketable securities

    182,823

    259,000

    Purchase of marketable securities

    (133,355
    )

    (179,021
    )

    Net cash provided by investing activities

    49,468

    78,041

    Cash Flows From Financing Activities:

    Proceeds from exercise of stock options

    17

    153

    Proceeds from issuance of common shares under the 2020 Employee Share Purchase Plan

    525

    689

    Net cash provided by financing activities

    542

    842

    Effect of exchange rate fluctuations on cash held

    (116
    )

    22

    Net Decrease In Cash And Cash Equivalents

    (26,551
    )

    (48,253
    )

    Cash and cash equivalents cash at beginning of year

    111,268

    159,521

    Cash and cash equivalents at end of year